NCT07543887

Brief Summary

investigation of body composition

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 12, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 4, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 4, 2026

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

April 5, 2026

Completed
17 days until next milestone

First Posted

Study publicly available on registry

April 22, 2026

Completed
Last Updated

April 22, 2026

Status Verified

April 1, 2026

Enrollment Period

2 years

First QC Date

April 5, 2026

Last Update Submit

April 14, 2026

Conditions

Thyroid Cancer

Keywords

thyroid

Outcome Measures

Primary Outcomes (1)

  • Total lean mass assessed by DXA (kg)

    Total lean body mass measured by dual-energy X-ray absorptiometry

    Baseline and 12 months

Secondary Outcomes (1)

  • 24-hour energy expenditure (kcal/day)

    Baseline and 12 months

Study Arms (1)

patient with advanced medullary thyroid cancer

patient with advanced medullary thyroid cancer

Other: observation in patient under treatmentDrug: Selpercatinib

Interventions

observation in patient under treatmentOTHER

observation in patient under treatment

patient with advanced medullary thyroid cancer
SelpercatinibDRUG

observational study of patients under selpercatinib

patient with advanced medullary thyroid cancer

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with thyroid cancer receiving ongoing treatment with selpercatinib

You may qualify if:

  • Adults (≥18 years old)
  • Diagnosis of thyroid cancer
  • Ongoing treatment with selpercatinib

You may not qualify if:

  • \- Inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Pisa

Pisa, PI, 56124, Italy

Location

MeSH Terms

Conditions

Thyroid NeoplasmsThyroid Diseases

Interventions

Observationselpercatinib

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

April 5, 2026

First Posted

April 22, 2026

Study Start

April 12, 2024

Primary Completion

April 4, 2026

Study Completion

April 4, 2026

Last Updated

April 22, 2026

Record last verified: 2026-04

Locations

IT(1)